Asymmetric synthesis of cis- and trans-γ-lactones useful in HIV-1 protease inhibitor synthesis

1994 ◽  
Vol 4 (7) ◽  
pp. 903-906 ◽  
Author(s):  
Michael P. Trova ◽  
Allan Wissner ◽  
Wellington T. Casscles ◽  
Grace C. Hsu
Keyword(s):  
Protease Inhibitor ◽  
Asymmetric Synthesis ◽  
Cis And Trans ◽  
Hiv 1

ChemInform Abstract: Asymmetric Synthesis of cis- and trans-γ-Lactones Useful in HIV- 1 Protease Inhibitor Synthesis.

ChemInform ◽  
2010 ◽  
Vol 25 (40) ◽  
pp. no-no
Author(s):  
M. P. TROVA ◽  
A. WISSNER ◽  
W. T. JUN. CASSCLES ◽  
G. C. HSU
Keyword(s):  
Protease Inhibitor ◽  
Asymmetric Synthesis ◽  
Cis And Trans ◽  
Hiv 1

Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor

1998 ◽  
Vol 63 (23) ◽  
pp. 8536-8543 ◽  
Author(s):  
Michael E. Pierce ◽  
Rodney L. Parsons ◽  
Lilian A. Radesca ◽  
Young S. Lo ◽  
Stuart Silverman ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Asymmetric Synthesis ◽  
Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

scholarly journals Simplification Therapy with Once‐Daily Emtricitabine, Didanosine, and Efavirenz in HIV‐1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial

2005 ◽  
Vol 191 (6) ◽  
pp. 830-839 ◽  
Author(s):  
Jean‐Michel Molina ◽  
Valérie Journot ◽  
Laurence Morand‐Joubert ◽  
Patrick Yéni ◽  
Willy Rozenbaum ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Randomized Trial ◽  
Viral Suppression ◽  
Once Daily ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document